학술논문
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients
Document Type
article
Author
Jens Peter Klussmann; Maria Grosheva; Peter Meiser; Clara Lehmann; Eszter Nagy; Valéria Szijártó; Gábor Nagy; Robert Konrat; Michael Flegel; Frank Holzer; Dorothea Groß; Charlotte Steinmetz; Barbara Scherer; Henning Gruell; Maike Schlotz; Florian Klein; Paula Aguiar de Aragão; Henning Morr; Helal Al Saleh; Andreas Bilstein; Belisa Russo; Susanne Müller-Scholtz; Cengizhan Acikel; Hacer Sahin; Nina Werkhäuser; Silke Allekotte; Ralph Mösges
Source
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Subject
Language
English
ISSN
2045-2322
Abstract
Abstract With the changing epidemiology of COVID-19 and its impact on our daily lives, there is still an unmet need of COVID-19 therapies treating early infections to prevent progression. The current study was a randomized, parallel, double-blind, placebo-controlled trial. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. Investigators assessed patients’ status throughout the trial including safety follow-ups (days 16 and 60). Symptoms were documented in patient diaries. Initial viral loads were log10 6.85 ± 1.31 (mean ± SD) copies/mL (ORF 1a/b gene). After treatment, virus load was reduced in all groups (p